Cargando…

Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study

OBJECTIVES: To clarify non-alcoholic fatty liver disease (NAFLD) prevalence, risk factors and clinical outcome in an exemplary Chinese population, a cohort of company employees was followed up for 11 years. DESIGN: Retrospective cohort study. SETTING: Between 2006 and 2016 in Ning bo, China. PARTICI...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xiaoping, Shi, Yanyan, Du, Juan, Hu, Keming, Zhou, Tingting, Chen, Lan, Zhang, Yanming, Li, Fujun, Zhang, Huier, Liebe, Roman, Meyer, Christoph, Dooley, Steven, Zhu, Zhongwei, Weng, Hong-Lei, Jia, Jinzhu, Huang, Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237861/
https://www.ncbi.nlm.nih.gov/pubmed/35760549
http://dx.doi.org/10.1136/bmjopen-2021-054891
_version_ 1784736895789432832
author Tang, Xiaoping
Shi, Yanyan
Du, Juan
Hu, Keming
Zhou, Tingting
Chen, Lan
Zhang, Yanming
Li, Fujun
Zhang, Huier
Liebe, Roman
Meyer, Christoph
Dooley, Steven
Zhu, Zhongwei
Weng, Hong-Lei
Jia, Jinzhu
Huang, Tong
author_facet Tang, Xiaoping
Shi, Yanyan
Du, Juan
Hu, Keming
Zhou, Tingting
Chen, Lan
Zhang, Yanming
Li, Fujun
Zhang, Huier
Liebe, Roman
Meyer, Christoph
Dooley, Steven
Zhu, Zhongwei
Weng, Hong-Lei
Jia, Jinzhu
Huang, Tong
author_sort Tang, Xiaoping
collection PubMed
description OBJECTIVES: To clarify non-alcoholic fatty liver disease (NAFLD) prevalence, risk factors and clinical outcome in an exemplary Chinese population, a cohort of company employees was followed up for 11 years. DESIGN: Retrospective cohort study. SETTING: Between 2006 and 2016 in Ning bo, China. PARTICIPANTS: 13 032 company employees. RESULTS: Over 11 years, the prevalence of NAFLD increased from 17.2% to 32.4% (men 20.5%–37% vs women 9.8%–22.2%). Male peak prevalence was between 40 and 60 years of age, whereas highest prevalence in women was at an age of 60 years and older. Logistic and Cox regression revealed 16 risk factors, including body mass index (BMI), albumin, white blood cell, triglycerides (TG), high-density lipoprotein, glutamyl transpeptidase, alanine transaminase, creatinine, urea acid, glucose, systolic blood pressure, diastolic blood pressure, blood sedimentation, haemoglobin, platelet and apolipoprotein B2 (p<0.05 for all factors). The area under the curve of these variables for NAFLD is 0.88. However, cause-effect analyses showed that only BMI, gender and TG directly contributed to NAFLD development. Over an 11-year follow-up period, 12.6%, 37.7% and 14.2% of male patients with NAFLD and 11.6%, 44.7% and 22.6% of female patients with NAFLD developed diabetes, hypertension and hyperuricaemia, respectively. Except one male patient who developed cirrhosis, no patients with NAFLD progressed into severe liver disease. CONCLUSION: Diabetes, hypertension and hyperuricaemia are the main clinical outcomes of NAFLD. Eleven years of NAFLD are not sufficient to cause severe liver disease. Age and obesity are direct risk factors for NAFLD. BMI, gender and TG are three parameters directly reflecting the occurrence of NAFLD.
format Online
Article
Text
id pubmed-9237861
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-92378612022-07-08 Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study Tang, Xiaoping Shi, Yanyan Du, Juan Hu, Keming Zhou, Tingting Chen, Lan Zhang, Yanming Li, Fujun Zhang, Huier Liebe, Roman Meyer, Christoph Dooley, Steven Zhu, Zhongwei Weng, Hong-Lei Jia, Jinzhu Huang, Tong BMJ Open Gastroenterology and Hepatology OBJECTIVES: To clarify non-alcoholic fatty liver disease (NAFLD) prevalence, risk factors and clinical outcome in an exemplary Chinese population, a cohort of company employees was followed up for 11 years. DESIGN: Retrospective cohort study. SETTING: Between 2006 and 2016 in Ning bo, China. PARTICIPANTS: 13 032 company employees. RESULTS: Over 11 years, the prevalence of NAFLD increased from 17.2% to 32.4% (men 20.5%–37% vs women 9.8%–22.2%). Male peak prevalence was between 40 and 60 years of age, whereas highest prevalence in women was at an age of 60 years and older. Logistic and Cox regression revealed 16 risk factors, including body mass index (BMI), albumin, white blood cell, triglycerides (TG), high-density lipoprotein, glutamyl transpeptidase, alanine transaminase, creatinine, urea acid, glucose, systolic blood pressure, diastolic blood pressure, blood sedimentation, haemoglobin, platelet and apolipoprotein B2 (p<0.05 for all factors). The area under the curve of these variables for NAFLD is 0.88. However, cause-effect analyses showed that only BMI, gender and TG directly contributed to NAFLD development. Over an 11-year follow-up period, 12.6%, 37.7% and 14.2% of male patients with NAFLD and 11.6%, 44.7% and 22.6% of female patients with NAFLD developed diabetes, hypertension and hyperuricaemia, respectively. Except one male patient who developed cirrhosis, no patients with NAFLD progressed into severe liver disease. CONCLUSION: Diabetes, hypertension and hyperuricaemia are the main clinical outcomes of NAFLD. Eleven years of NAFLD are not sufficient to cause severe liver disease. Age and obesity are direct risk factors for NAFLD. BMI, gender and TG are three parameters directly reflecting the occurrence of NAFLD. BMJ Publishing Group 2022-06-27 /pmc/articles/PMC9237861/ /pubmed/35760549 http://dx.doi.org/10.1136/bmjopen-2021-054891 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Gastroenterology and Hepatology
Tang, Xiaoping
Shi, Yanyan
Du, Juan
Hu, Keming
Zhou, Tingting
Chen, Lan
Zhang, Yanming
Li, Fujun
Zhang, Huier
Liebe, Roman
Meyer, Christoph
Dooley, Steven
Zhu, Zhongwei
Weng, Hong-Lei
Jia, Jinzhu
Huang, Tong
Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study
title Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study
title_full Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study
title_fullStr Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study
title_full_unstemmed Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study
title_short Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study
title_sort clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study
topic Gastroenterology and Hepatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237861/
https://www.ncbi.nlm.nih.gov/pubmed/35760549
http://dx.doi.org/10.1136/bmjopen-2021-054891
work_keys_str_mv AT tangxiaoping clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT shiyanyan clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT dujuan clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT hukeming clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT zhoutingting clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT chenlan clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT zhangyanming clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT lifujun clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT zhanghuier clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT lieberoman clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT meyerchristoph clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT dooleysteven clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT zhuzhongwei clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT wenghonglei clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT jiajinzhu clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy
AT huangtong clinicaloutcomeofnonalcoholicfattyliverdiseasean11yearfollowupstudy